PCSK9 Inhibitor
-
PCSK9-IN-31
0 ImagesCat. No.: HY-161942CAS No.: 2247649-76-7PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats.
-
PCSK9-IN-14
0 ImagesCat. No.: HY-153391CAS No.: 2913198-84-0PCSK9-IN-14 (compound Ia-8) is a potent PCSK9 inhibitor.
-
PCSK9-IN-38
0 ImagesCat. No.: HY-189212CAS No.: 3126488-23-8
-
Inclisiran sodium scrambled negative control
0 ImagesCat. No.: HY-132591CInclisiran sodium scrambled negative control is the sequence scrambled negative control of Inclisiran sodium.
-
PCSK9-IN-17
0 ImagesCat. No.: HY-153453CAS No.: 2455424-72-1PCSK9-IN-17 is a PCSK9 inhibitor. PCSK9-IN-17 can be used for the research of cholesterol metabolism (WO2020150474A1, compound 105).
-
ALD306
0 ImagesCat. No.: HY-P991343Synonyms: ALD309ALD306 is a human monoclonal antibody (mAb) targeting PCSK9. ALD306 can be used in Hypercholesterolaemia research.
-
PCSK9-IN-36
0 ImagesCat. No.: HY-187677CAS No.: 94159-34-9PCSK9-IN-36 is a PCSK9 inhibitor and a flavonoid glycoside derivative. PCSK9-IN-36 binds stably within the surface groove of PCSK9 through hydrophobic interactions involving its flavonoid scaffold and an electrostatic hydrogen-bonding network formed by its polar glycosidic group, thereby competitively blocking the interaction between PCSK9 and the low-density lipoprotein receptor (LDLR). PCSK9-IN-36 can be used for research on hypercholesterolemia.
-
PCSK9-IN-24
0 ImagesCat. No.: HY-163141CAS No.: 2974496-96-1PCSK9-IN-24 (Compound OY3) is a compound that targets PCSK9. PCSK9-IN-24 reduces PCSK9 levels and increases LDL uptake and may be used in atherosclerosis research.
-
PCSK9 Inhibitor, EGF-A
0 ImagesCat. No.: HY-P11071PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor with LDLR degradation inhibitory activity and LDLR recycling promoting activity. PCSK9 Inhibitor, EGF-A is a synthetic peptide consisting of 42 amino acid residues, which contains the calcium-binding site of the epidermal growth factor A domain (EGF-A). PCSK9 Inhibitor, EGF-A reduces plasma LDL cholesterol levels by maintaining hepatic LDLR levels and enhancing the clearance capacity of circulating LDL. PCSK9 Inhibitor, EGF-A can be used in research related to hypercholesterolemia, premature atherosclerosis, coronary heart disease and familial hypercholesterolemia.
-
PCSK9-IN-15
0 ImagesCat. No.: HY-153451CAS No.: 2455423-94-4PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, KD <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia.
-
MeIm
0 ImagesCat. No.: HY-161941CAS No.: 2043947-71-1
-
SPC4061 sodium
0 ImagesCat. No.: HY-148689ASPC4061 an antisense nucleotide, sodium is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases.
-
PCSK9-IN-1
0 ImagesCat. No.: HY-134482CAS No.: 2730022-10-1PCSK9-IN-1 is a novel and highly potent cyclic peptide PCSK9 inhibitor with a Ki value of 1.46 nM.
-
Anacetrapib (Standard)
0 ImagesSynonyms: MK-0859 (Standard)Anacetrapib (Standard) is the analytical standard of Anacetrapib. This product is intended for research and analytical applications. Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
-
PCSK9-IN-33
0 ImagesCat. No.: HY-175189PCSK9-IN-33 (Compound 1'f) is a PCSK9 inhibitor with an IC50 of 161 nM. PCSK9-IN-33 can be used for hypercholesterolemia research.
-
SBC-110736 (Standard)
0 ImagesCat. No.: HY-101832RCAS No.: 1629166-02-4SBC-110736 (Standard) is the analytical standard of SBC-110736 (HY-101832). This product is intended for research and analytical applications. SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1.
